View More Recent Stories
-
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoVal
-
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
-
enVVeno Medical (NVNO) Prices 4.3M Share and Warrant Offering at $3.50/sh
-
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
-
enVVeno Medical (NVNO) Announces Proposed Share Offering
-
enVVeno Medical Corporation Announces Proposed Public Offering
-
enVVeno Medical (NVNO) Appoints Sandy Prietto as VP of Marketing
-
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
-
enVVeno Medical (NVNO) Provides Update on FDA Premarket Approval Application Status for VenoValve
-
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
-
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
-
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
-
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
-
enVVeno Medical (NVNO) Reports Positive Interim Venous Ulcer Healing Data
-
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular A
-
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
